Business Context and Reporting Period
This Form 8-K was filed by ILLUMINA, INC. on November 27, 2016. The report addresses a specific corporate governance event regarding the departure of a senior executive.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of Tristan Orpin, Executive Vice President of Clinical Genomics. Mr. Orpin notified the company on November 27, 2016, that he would be leaving in January 2017.
Outlook and Management Commentary
Management has identified and agreed to employment terms with a successor to Mr. Orpin. The successor is scheduled to join the company in January 2017, ensuring continuity in the role.
Key Facts for Investor Verification
- Tristan Orpin, EVP of Clinical Genomics, is departing in January 2017.
- A successor has been identified and will assume the role in January 2017.
- No financial data or guidance is included in this specific filing.